Tektronix, Inc., a leading worldwide provider of measurement solutions, today introduced the 6 Series MSO mixed signal oscilloscope. The new oscilloscope extends the performance threshold of midrange oscilloscopes to 8 GHz and delivers a 25 GS/s sample rate simultaneously on all 4 channels – an industry first for this class of oscilloscope – to accommodate the needs of designers working on faster, more complex embedded systems designs. With 25 GS/s sample rate on all channels, designers can accurately now view up to four high-speed signals at one time. For example, a DDR3 clock and three DDR3 data channels can be viewed and analyzed simultaneously, decreasing the time it takes to fully characterize a design with an instrument that shares sampling systems between channels.
The new 6 Series MSO also boosts measurement confidence with its low-noise inputs especially at the highest sensitivity settings where it matters most. For example, modern embedded designs require clean, precisely-controlled DC power supplies to feed ASIC and FPGA devices. For such applications, the 6 Series MSO enables designers to measure DC power rails with more resolution and accuracy, reducing the time it takes to understand high frequency influencers on power rails in a design.
To view the multimedia release go to:
https://www.multivu.com/players/English/7990952-tektronix-6-series-mso-mixed-signal-oscilloscope/
GW Pharmaceuticals plc (Nasdaq: GWPH, “GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, along with its U.S. subsidiary Greenwich Biosciences, announced today that The New England Journal of Medicine has published results from a Phase 3 study of Epidiolex® (cannabidiol) in children with Dravet syndrome.1 Epidiolex, GW’s lead product candidate and the potential first in a new category of anti-epileptic drugs, is a liquid formulation of purified, plant-derived cannabidiol (CBD), a non-psychoactive cannabinoid, which is being studied for the treatment of a number of rare, severe pediatric-onset epilepsy disorders. In the study, Epidiolex significantly reduced monthly convulsive seizure frequency compared to placebo in highly treatment-resistant children when added to existing treatment. Treatment with Epidiolex was generally well tolerated, with a safety profile consistent with prior open label experience.
To view the multimedia release go to:
https://www.multivu.com/players/uk/8109951-gw-pharmaceuticals-study-epidiolex/
Abila, the leading provider of software and services to nonprofits, associations, and government entities, today announced findings from its Donor Loyalty Study: A Deep Dive into Donor Behaviors and Attitudes. The study is an extension of Abila’s Donor Engagement Study from 2015, and provides a much more detailed look at specific attitudes and behaviors of donors; type, length, and frequency of content that resonates with donors; the importance of personalization; and how donors view the use of donated dollars.
The study also includes insights across four generations (Millennials, Generation Xers, Boomers, and Matures), as well as a special section on high-wealth donors (those who make more than $200,000 annually).
To view the multimedia release go to:
http://www.multivu.com/players/English/7802151-abila-donor-loyalty-study/
TriggerPoint™, the market leader in foam rolling, movement products and education, today announces the launch of the GRID VIBE premium vibrating foam roller. Designed for muscle relaxation and pain reduction, the GRID VIBE pairs TriggerPoint’s patented GRID foam roller design with vibration technology to deliver enhanced muscle mobility experiences.
The GRID VIBE’s vibration frequency is specifically calibrated at 33 hertz for optimal muscle relaxation, minimizing discomfort and allowing users to focus longer on foam rolling tender areas. Research shows that vibration decreases the body’s sensation of pain. When vibration is paired with TriggerPoint’s signature GRID pattern that mimics a massage therapist’s hands, fingers and fingertips, the GRID VIBE effectively targets more layers of tight muscle tissue. The GRID VIBE can be used by anyone for muscle recovery, injury prevention, improving athletic performance, pain management, or boosting overall body movement and mobility.
To view the multimedia release go to:
https://www.multivu.com/players/English/8135751-triggerpoint-grid-vibe-vibrating-foam-roller/
TriggerPoint™, the market leader in foam rolling, movement products and education, today announces the launch of the GRID VIBE premium vibrating foam roller. Designed for muscle relaxation and pain reduction, the GRID VIBE pairs TriggerPoint’s patented GRID foam roller design with vibration technology to deliver enhanced muscle mobility experiences.
The GRID VIBE’s vibration frequency is specifically calibrated at 33 hertz for optimal muscle relaxation, minimizing discomfort and allowing users to focus longer on foam rolling tender areas. Research shows that vibration decreases the body’s sensation of pain. When vibration is paired with TriggerPoint’s signature GRID pattern that mimics a massage therapist’s hands, fingers and fingertips, the GRID VIBE effectively targets more layers of tight muscle tissue. The GRID VIBE can be used by anyone for muscle recovery, injury prevention, improving athletic performance, pain management, or boosting overall body movement and mobility.
To view the multimedia release go to:
https://www.multivu.com/players/English/8135751-triggerpoint-grid-vibe-vibrating-foam-roller/
